Patents by Inventor Gerhard Siemeister

Gerhard Siemeister has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190284206
    Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: March 21, 2019
    Publication date: September 19, 2019
    Applicants: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Marion HITCHCOCK, Anne MENGEL, Vera PÜTTER, Gerhard SIEMEISTER, Antje Margret WENGNER, Hans BRIEM, Knut EIS, Volker SCHULZE, Amaury Ernesto FERNANDEZ-MONTALVAN, Stefan PRECHTL, Simon HOLTON, Jörg FANGHÄNEL, Philip LIENAU, Cornelia PREUSSE, Mark Jean GNOTH
  • Patent number: 10350206
    Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: July 16, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Anne Mengel, Hans-Georg Lerchen, Manfred Möwes, Thomas Müller, Lars Bärfacker, Marion Hitchcock, Arwed Cleve, Joachim Kuhnke, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Ursula Mönning, Simon Holton
  • Patent number: 10308629
    Abstract: Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: June 4, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith Graham, Ulrich Klar, Hans Briem, Gerhard Siemeister, Ursula Mönning
  • Publication number: 20190142812
    Abstract: The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: January 6, 2017
    Publication date: May 16, 2019
    Inventors: Ulrich LÜCKING, Marcus KOPPITZ, Julien LEFRANC, Lars WORTMANN, Antje Margret WENGNER, Gerhard SIEMEISTER, Ulf BÖMER, Benjamin BADER, Philip LIENAU, Hans SCHICK
  • Patent number: 10266548
    Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 23, 2019
    Assignees: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Marion Hitchcock, Anne Mengel, Vera Pütter, Gerhard Siemeister, Antje Margret Wengner, Hans Briem, Knut Eis, Volker Schulze, Amaury Ernesto Fernandez-Montalvan, Stefan Prechtl, Simon Holton, Jörg Fanghänel, Philip Lienau, Cornelia Preusse, Mark Jean Gnoth
  • Patent number: 10227299
    Abstract: Compounds of formula (I) as described herein processes for their production and their use as anti-cancer agents.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: March 12, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith Graham, Ulrich Klar, Hans Briem, Gerhard Siemeister, Ursula Mönning, Jozsef Balint
  • Patent number: 10214542
    Abstract: The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: February 26, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Daniel Hog, Jens Geisler, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Gerhard Siemeister, Nicolas Werbeck
  • Publication number: 20180282346
    Abstract: The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: September 30, 2016
    Publication date: October 4, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich LÜCKING, Daniel HOG, Jens GEISLER, Arne SCHOLZ, Kirstin PETERSEN, Philip LIENAU, Christian STEGMANN, Dorothee ANDRES, Gerhard SIEMEISTER, Nicolas WERBECK
  • Publication number: 20180273548
    Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: September 26, 2016
    Publication date: September 27, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich LÜCKING, Jens GEISLER, Daniel HOG, Arne SCHOLZ, Kirstin PETERSEN, Philip LIENAU, Christian STEGMANN, Dorothee ANDRES, Kunzeng ZHENG, Ping GAO, Gang CHEN, Jiajun XI, Simon Anthony HERBERT, Gerhard SIEMEISTER, Nicolas WERBECK
  • Publication number: 20180256591
    Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 13, 2018
    Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
  • Publication number: 20180222881
    Abstract: Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: August 1, 2016
    Publication date: August 9, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Gerhard SIEMEISTER, Ursula M?NNING
  • Patent number: 9993484
    Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: June 12, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars Wortmann, Ulrich Lücking, Julien LeFranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
  • Publication number: 20180155285
    Abstract: Compounds of formula (I) as described hereinprocesses for their production and their use as anti-cancer agents.
    Type: Application
    Filed: June 14, 2016
    Publication date: June 7, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Gerhard SIEMEISTER, Ursula MÕNNING, Jozsef BALINT
  • Patent number: 9962389
    Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 8, 2018
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht
  • Patent number: 9963464
    Abstract: The present invention relates to novel macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: May 8, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich Lücking, Pierre Wasnaire, Arne Scholz, Philip Lienau, Gerhard Siemeister, Christian Stegmann, Ulf Bömer, Kunzeng Zheng, Ping Gao, Gang Chen, Jiajun Xi
  • Patent number: 9902716
    Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). R2 represents the group (a).
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: February 27, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Dirk Kosemund, Ulrich Lücking, Gerhard Siemeister, Arne Scholz, Philip Lienau
  • Patent number: 9884849
    Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: February 6, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Dirk Kosemund, Ulrich Lücking, Gerhard Siemeister, Arne Scholz, Philip Lienau
  • Patent number: 9877954
    Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: January 30, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich Lücking, Niels Böhnke, Arne Scholz, Philip Lienau, Gerhard Siemeister, Ulf Bömer, Dirk Kosemund, Rolf Bohlmann, Ludwig Zorn
  • Publication number: 20180016272
    Abstract: Compound of formula (I), processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: January 25, 2016
    Publication date: January 18, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Volker SCHULZE, Gerhard SIEMEISTER, Philip LIENAU, René TEMPEL, Jozsef BÁLINT
  • Patent number: 9856242
    Abstract: The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: January 2, 2018
    Assignee: Bayer Pharma Aktiengesellscaft
    Inventors: Dirk Kosemund, Ulrich Lücking, Arne Scholz, Gerhard Siemeister, Philip Lienau